Comprehensive Board Review Notes: Hyponatremia, Acid-Base, and Electrolyte Disorders (PDF notes)

Na, K, & Acid-base: Comprehensive board notes

• Purpose: study notes distilled from a nephrology board review deck; includes testing formats, study strategies, and detailed content on hyponatremia, acid-base disorders, electrolyte derangements, and nephrolithiasis.

• Note on format: notes are organized as top-level sections with bullet points and LaTeX-formatted equations where appropriate.

ABIM testing, study approach, and blueprint references

• Exam formats and timing (selected details):

  • Initial Certification/Board Exam: In-Center Testing; 4 blocks of 60 questions; 2 hours per block; 100 minutes of break time; annual windows (e.g., Nov 20, 2023; Nov 14, 2024); valid 10 years.

  • MOC Examination: In-Center Testing; 4 blocks of 60 questions; 2 hours per block; 100 minutes break; open book with UpToDate; twice per year; valid 10 years.

  • Longitudinal Knowledge Assessment (At Home): 30 questions per quarter; 4 minutes per question; ongoing over 5 years; if not passed, usual test within 1 year.

• Key objectives: tips to improve test success, test structure details, time management, targeted study approaches, board-question strategies, and a sample study schedule.

• Exam resources and blueprints: ABIM framework and detailed blueprints for nephrology; links provided in the deck.

• Testing and study pattern concepts (from distribution of techniques):

  • High-yield techniques: Pre-quiz before reading; practice testing; distributed practice; recall over rereading.

  • Low to moderate-yield: rereading; highlighting; mnemonics (low yield); summarization (moderate yield).

  • Spaced practice yields better retention than massed practice; recall/recall-based strategies outperform simple rereading.

  • Passive reading is associated with wasted time and more wrong answers if text is under-highlighted.

• Reading & note-taking guidance:

  • Focus on headings, intro, and summaries; summarize while reading; diagram/outline to connect to prior knowledge; space re-reading; avoid excessive highlighting.

• Mnemonics and elaborative techniques:

  • Mnemonics: low-yield for long-term retention due to time to create vs benefit.

  • Elaborative interrogation and self-explanation: moderate yield; connect new with prior knowledge; examples include distinguishing fine biopsy findings in nephrotic syndromes, IgA nephropathy nuances, etc.

• Practice testing and spaced practice: high-yield; use practice problems, flashcards, and spaced sessions; emphasize cued recall and interleaved practice when possible.

• Question-approach and pitfalls: read vignette first, scan answer options, then read vignette in detail to validate each distractor; beware of 2-step cognitive tasks (diagnosis + next step).

• KSAP and NephSAP: board-review resources; official ASN materials; use them to reinforce topics and plan weekly study blocks.

• Summary study approach: plan, schedule, and maintain notes; use flashcards or question banks; integrate prior knowledge with new content; practice questions, spaced review, and topic interleaving.

• Key formulas and units (for quick reference in the notes):

  • Adrogue–Madias formula (predict rise in serum [Na+] after hypertonic saline or other Na+ infusions):
    $ext{Δ[Na^+] }= rac{ ext{Na}<em>{infusate}- ext{Na}</em>{serum}}{TBW+1}$

  • Water deficit (hypernatremia management; assume total body water TBW ≈ 0.6 × weight [kg]):
    $ext{Water deficit} = TBW imes \bigl(1- rac{140}{[ ext{Na}^+]}\bigr)$

  • TBW estimates (general):

  • Male: TBW ≈ 0.60 × weight; Female: TBW ≈ 0.50 × weight (typical guidelines).

  • Free water clearance (to understand solute-free water handling):
    $CH<em>2O = V imes \bigl(1- rac{U</em>{osm}}{P_{osm}}\bigr)$

  • Elaborative form for urine water handling (Diuretics/solute load):
    $CH<em>2O</em>e = V imes \bigl(1- rac{U<em>{Na}+U</em>{K}}{P_{Na}}\bigr)$

  • Urine anion gap (UAG):
    $UAG = U<em>{Na} + U</em>{K} - U_{Cl}$

  • Urine osmolal gap (UOG) for NH4+ assessment in metabolic acidosis: measure NH4+ indirectly via osmolality

  • Serum osmolality (calculated):
    $ext{Posm}<em>{calc} = 2[Na^+] + rac{BUN}{2.8} + rac{Glucose}{18} \ ext{Osmolal gap} = ext{Posm}</em>{measured} - ext{Posm}_{calc}$.

  • Anion Gap (AG):
    $AG = [Na^+] - ([Cl^-] + [HCO_3^-])$

  • Delta Gap (to assess mixed patterns):
    $ext{Delta Gap} = AG - AG_{normal} ext{ (typically }12 ext{)}$

  • Winter’s formula (expected pCO2 in AG metabolic acidosis):
    $pCO<em>2 ext{ (predicted)} \,=\ 1.5 imes [HCO</em>3^-] + 8 \,\pm\ 2$

  • Normal anion gap acidosis (NAGMA) etiologies include GI bicarbonate loss, proximal/distal RTA, etc.

Hyponatremia: patterns, diagnosis, and management

• Definitions and clinical spectrum

  • Hyponatremia: serum Na+ < 135 mEq/L; severity and symptoms vary (acute vs chronic, symptomatic vs asymptomatic).

  • Acute hyponatremia (<48 h) can cause cerebral edema; chronic hyponatremia carries risk of osmotic demyelination if corrected too quickly.

  • Consequences include gait disturbances, falls, neurocognitive impairment, seizures, coma, and increased mortality with inappropriate management.

• SIADH and euvolemic hyponatremia (core features)

  • High urine osmolality in presence of low serum osmolality; urine Na+ often >40 mEq/L; clinically euvolemic.

  • Typical signs: no edema, normal thyroid/adrenal function, no diuretic effect, and absence of heart/renal failure.

  • Mechanism: non-osmotic AVP secretion causing water retention; SIADH is common in cancer, pulmonary disease, CNS disorders; can be drug-induced (e.g., certain antidepressants, anticonvulsants).

• Diagnosis (key lab clues)

  • Serum osmolality: hypo-osmolar hyponatremia if Posm < 275 mOsm/kg; hyperosmolar substitutions are different etiologies.

  • Urine osmolality (Uosm): typically >100 mOsm/kg in SIADH and most hyponatremias with AVP present.

  • Urine Na+ (Una): often >40 mEq/L in SIADH; low Una suggests hypovolemic or reset osmostat or other etiologies.

• Practical management principles for hyponatremia (board relevance)

  • Acute symptomatic hyponatremia (seizure, coma): hypertonic saline bolus (3% NaCl) 100 mL IV over 10 minutes, may repeat x2 if needed; monitor every 5-10 minutes initially, then q1-2 h.

  • In-hospital management for non-emergent hyponatremia: cautious correction with hypertonic saline boluses or isotonic saline depending on volume status; consider a vaptan (vasopressin receptor antagonist) if appropriate and not in hypovolemic state.

  • Vasopressin antagonists (vaptans): Conivaptan (IV) and Tolvaptan (oral). Effect: increase free water excretion and raise serum Na+; monitor for overcorrection and liver toxicity (tolvaptan) and liver function before long-term use.

  • Urea therapy: an option for SIADH/hyponatremia when fluid restriction is insufficient or not tolerated; increases solute load to promote water excretion.

  • Demeclocycline: rarely used due to delay in onset and nephrotoxicity risk; alternative in SIADH if other therapies fail.

  • Fluid restriction: typically 0.8 L/day as a starting point in SIADH; poor adherence and limited effectiveness in some patients.

  • Important caution: risk of osmotic demyelination syndrome (ODS) with overly rapid correction; recommended correction rates: raise Na+ by <8-12 mEq/L in first 24 h and <18-24 mEq/L in 48 h (for chronic hyponatremia).

  • In cases of excessive correction (overcorrection), strategies include DDAVP (to re-lower Na+) and controlled re-lowering with hypertonic saline or D5W; frequent monitoring is essential.

• Marathon runners and other scenarios

  • Exercise-associated hyponatremia can occur due to non-suppressible AVP release, exercise-induced SIADH, and substantial fluid intake.

  • Field treatment for acute symptomatic hyponatremia in marathon runners: 3% saline 100 mL bolus, repeated up to 300 mL depending on response; hospital protocols for rapid correction are similar to other severe hyponatremias.

• Practical examples and case-type takeaways

  • Case-wise approach usually starts with assessing tonicity, AG, and then the delta gap to decide if there’s an AG metabolic acidosis, NAGMA, or mixed patterns.

  • SIADH often presents with euvolemia, hyponatremia, low serum osmolality, high Uosm, high Una, and normal renal/hepatic/cardiac function.

  • First-line acute symptomatic hyponatremia treatment is a 100 mL of 3% NaCl bolus (repeat up to 2 times as needed); ongoing therapy tailored to volume status and correction goals.

• Important notes on SIADH, hyponatremia and treatment caveats

  • Hypertonic saline must be used cautiously; overly rapid correction can cause osmotic demyelination, especially in chronic hyponatremia.

  • DDAVP can be used to re-lower Na+ if over-correction occurs (re-induction of water retention).

  • Vasopressin antagonists can cause rapid correction if used with aggressive free water excretion; require frequent Na+ checks.

  • Urea can be an effective, kidney-safe option for SIADH when fluid restriction fails or is poorly tolerated.

Hypernatremia: pathophysiology, diagnosis, and management

• Definitions and epidemiology

  • Hypernatremia results from a relative deficit of water in relation to sodium; common in the hospital due to volume depletion, poor access to water, or diabetes insipidus (DI).

  • Water deficit calculation aids planning therapy; urine osmolality helps distinguish DI types.

• Diagnostic framework and equations

  • Water deficit (case-based):
    $ext{Water deficit} = TBW imes \bigl(1- rac{[ ext{Na}^+]}{140}\bigr)$

  • Free water deficit can be estimated using TBW, and predicted deficit is corrected with hypotonic fluids (D5W or half-normal saline depending on context).

  • Urine osmolality and urine output guide therapy:

  • In DI, urine osmolality is inappropriately low (low Uosm) and urine output is high.

  • In SIADH or other hyponatremic states with DI-like features, urine osmolality can be high.

• Management principles

  • Correct slowly to avoid cerebral edema in chronic hypernatremia; rate of correction typically not to exceed 0.5 mEq/L per hour or ~10 mEq/L per 24 h in many guidelines.

  • In acute hypernatremia, more rapid correction may be tolerated with careful monitoring.

  • In CRRT (continuous renal replacement therapy), sodium algorithms are used to prevent rapid rise in Na+. Adjust circuits, use post-filter fluids (e.g., D5W), and monitor Na+ every 1-2 hours during correction.

  • Drug therapies in DI-related hypernatremia: desmopressin (DDAVP) to test/assess DI type; treat underlying cause; consider vasopressin antagonists in SIADH-like scenarios where water retention is excessive (not typically in hypernatremia cases).

• Special notes from the deck

  • In nephrology exam questions, the determinant is often whether urine osmolality is high or low, the presence of DI vs SIADH, and the rate at which Na+ changes with therapy.

  • The role of aquaretics (vaptans) and urea therapy in hypernatremia is nuanced and depends on volume status and underlying etiology.

Acid-base disorders: core principles and tools

• Five-step framework (board-style approach)
  1) Determine acidemia (pH < 7.36) or alkalemia (pH > 7.44).
  2) Determine the primary disturbance (metabolic vs respiratory).
  3) Calculate the anion gap (AG): $AG=[Na^+]-([Cl^-]+[HCO_3^-])$ and compare to normal ~12 (lab-dependent).
  4) Assess compensation (respiratory for metabolic disturbances; metabolic for respiratory disturbances).
  5) Use the 1:1 relationship for AG metabolic acidosis (HCO3- ≈ AG on simple patterns).

• Common patterns and formulas

  • Winter’s formula for primary metabolic acidosis (predictive):
    $pCO<em>2^{pred} = 1.5 imes [HCO</em>3^-] + 8 \, (±2).$

  • Delta gap approach for mixed AG and non-AG metabolic acidosis: compare Delta AG to Delta HCO3- to detect mixed disorders.

  • Urine anion gap (UAG) as a surrogate for NH4+ excretion in metabolic acidosis:
    $UAG = U<em>{Na} + U</em>{K} - U_{Cl}.$

  • Urine osmolality gap (UOG) can help gauge NH4+ excretion; a large gap supports high NH4+ excretion and a properly functioning distal nephron.

  • Urine pH and UAG help differentiate distal RTA (positive UAG, UpH > 5.5) vs proximal RTA (proximal bicarbonate loss with increased proximal bicarbonate reclamation, often with low UAG).

• Normal anion gap metabolic acidosis (NAGMA) vs AG metabolic acidosis

  • AG metabolic acidosis suggests accumulation of unmeasured anions (lactate, ketoacids, uremic acids, etc.).

  • NAGMA suggests loss of bicarbonate or impaired bicarbonate generation (diarrhea, RTA, acetazolamide, spironolactone, etc.).

• DKA and lactic acidosis: dynamic interplay between AG and non-AG components during recovery; osmolal gap and lactate dynamics can change with therapy (e.g., insulin therapy and fluid management).

• Hyperkalemia and acidosis interplay: K+ and H+ exchange across cells affects acid-base balance; K+ status can influence NH4+ production and bicarbonate generation.

• Distal and proximal RTA: distinguishing features

  • Distal RTA (type 1): impaired distal H+ secretion, UpH > 5.5, positive UAG, renal stone risk due to alkaline urine and calcium phosphate stones.

  • Proximal RTA (type 2): bicarbonate wasting with proximal reabsorption defect; urine pH can be variable; typically a bicarbonaturia with variable NH4+ excretion; often a Fanconi syndrome pattern if generalized.

• Metabolic alkalosis: generation and maintenance

  • Usually due to H+ loss or bicarbonate retention; chloride depletion (low urine Cl-) indicates chloride-sensitive alkalosis; high urine Cl- suggests chloride-resistant alkalosis (e.g., mineralocorticoid excess, Bartter/Gitelman, diuretic use).

  • Urine chloride as a key discriminator:

  • UCl- < 20 mEq/L: chloride-responsive alkalosis (vomiting, NG suction, diuretics "off" phase, cystic fibrosis, etc.).

  • UCl- > 30 mEq/L: chloride-resistant alkalosis (hyperaldo, Cushing’s, edematous states, amiloride use, Bartter, Gitelman, etc.).

• Practical acid-base takeaways

  • Always compute AG and delta AG; consider mixed AG and non-AG patterns when pH is near normal.

  • Use UAG and UOG to evaluate ammonium handling in acidosis; positive UAG suggests distal acidification defect (D-RTA).

  • Consider osmolality gaps for ingestion/toxins (methanol, ethylene glycol, isopropanol, toluene, propylene glycol, etc.).

  • In DKA, after insulin therapy, a normal-gap acidosis can emerge due to loss of ketone buffer and bicarbonate shifts; careful monitoring required.

Hyponatremia in detail (case-based insights)

• Case highlights and teaching points

  • SIADH pattern: euvolemic hyponatremia with high Una and high Uosm; common causes include CNS disease, malignancies, pulmonary disease, drugs.

  • Hyponatremia treatment anchors:

  • Acute symptomatic hyponatremia: hypertonic saline bolus (3% NaCl) 100 mL x 2-3 as needed with close monitoring; avoid overly rapid correction.

  • Chronic hyponatremia: fluid restriction; consider vasopressin antagonists; if risk of overcorrection, DDAVP can be used to control rate.

  • Severe hyponatremia with persistent symptoms: hypertonic saline boluses with vigilant monitoring; ensure not to overshoot correction.

  • vaptans: Conivaptan (IV) and Tolvaptan (oral) demonstrated efficacy in increasing [Na+]; watch for liver toxicity (tolvaptan); avoid hypovolemic patients.

  • Urea: effective in SIADH when fluid restriction is insufficient or not tolerated; increases solute load and promotes water excretion.

• Practical takeaways for exam prep

  • Distinguish hyponatremia due to SIADH from hypovolemic and reset osmostat etiologies by assessing clinical volume status, Una, Uosm, and renal function.

  • Use the AG and delta gaps to identify mixed etiologies; key patient management pivots hinge on rate of Na+ correction and neuro status.

  • In marathon runners and exertional hyponatremia, field protocols emphasize rapid 3% NaCl boluses when symptomatic.

Hypernatremia: mechanism, assessment, and management nuances

• Water deficit approach: quantify water deficit using TBW and Na+; correct at a safe rate depending on duration of hypernatremia.

• Special considerations for DI (central vs nephrogenic): free water losses vs water intake; HOUSING therapy with DDAVP in differential testing.

• CRRT and tutoring on Na+ control: practical strategies include adjusting circuit composition and post-filter fluids to control the Na+ rise rate.

Acute and chronic hyponatremia case patterns and osmolar considerations

• Osmolality gaps and pseudo-hyponatremia

  • Pseudo-hyponatremia occurs with extreme hyperlipidemia or hyperproteinemia; direct vs indirect measurement distinguishes true hyponatremia.

  • Direct potentiometry vs indirect (autoanalyzers) differences can mislead Na+ measurement in very lipemic or hyperproteinemic samples.

• Osmolal gap and the toxins

  • Measured osmolality minus calculated osmolality helps identify ingestions (methanol, ethylene glycol, propylene glycol, isopropanol, toluene, ethanol).

• Case lessons and clinical reasoning tips

  • In DKA with hyperglycemia, apparent hyponatremia can occur due to osmotic shift; consider osmolality-based adjustments for true sodium values.

  • For intoxications (methanol, ethylene glycol, toluene), use osmolal gap and UAG/UOG in the differential; treat toxidromes accordingly.

Acute kidney injury (AKI) and diuretic strategies in electrolyte disorders

• Diuretic resistance and RAAS activation

  • High distal Na+ delivery and mineralocorticoid activity drive K+ wasting and metabolic alkalosis in Bartter-like states.

  • Diuretic resistance occurs when neurohormonal responses counteract diuretic effects; strategies include higher-dose loop diuretics, thiazides, K-sparing diuretics, and addressing volume status.

• Albumin and diuretics in edema management

  • Albumin co-administration with loop diuretics can transiently increase diuresis, especially in nephrotic states, but magnitude is variable; often used in nephrotic-presentation diuretic strategy.

• Osmotic diuresis and electrolyte disturbances

  • DKA, lactic acidosis, and toxin-induced osmolal gaps can change Na+ and K+ handling; management requires balancing fluid and electrolyte corrections with insulin (if needed) and hemodynamics.

Hypomagnesemia and potassium handling: focused concepts

• Magnesium physiology and transport

  • TRPM6/TRPM7 channels and claudin regulation (CLDN16/CLDN19) are central to Mg handling in gut and kidney.

  • EGFR signaling modulates TRPM6 trafficking to the apical membrane; cetuximab (EGFR inhibitor) can cause hypomagnesemia by downregulating TRPM6.

  • Hypomagnesemia commonly coexists with hypocalcemia due to PTH axis effects; Mg is necessary for PTH release and receptor function.

• Common etiologies for hypomagnesemia in nephrology

  • Diuretic use (especially loop diuretics) and chronic diarrhea; proton pump inhibitors (PPI) are a common non-renal cause (via TRPM6 suppression).

  • Gitelman syndrome (NCCT mutations), Bartter syndrome (NKCC2/ROMK/ClC-Kb defects) mimic thiazide/loop diuretic effects and present with hypomagnesemia and hypokalemia.

  • Immunosuppressive medications like calcineurin inhibitors can worsen Mg wasting by downregulating TRPM6/EGF axis; docking with Bartter/Gitelman phenotypes.

• Clinical implications and treatment

  • Magnesium supplementation (oral or IV) is the mainstay for symptoms; correction rates depend on severity and comorbidities.

  • In cases of hypomagnesemia with hypokalemia, correction of Mg often improves K+ handling; magnesium repletion is a prerequisite for K+ normalization in some conditions.

Potassium disorders: overview and pathophysiology

• Normal potassium homeostasis: intracellular predominance; daily intake and renal excretion balance; major kidneys processes: proximal reabsorption, TAL reabsorption (NKCC2), distal delivery, ROMK channel secretion, ENaC-driven luminal potential, and H+/K+-ATPase balance.

• Hypokalemia etiologies and mechanisms

  • Cell shift due to alkalosis, insulin, beta-adrenergic activity; GI losses; renal tubular disorders (Bartter/Gitelman, Liddle syndrome).

  • Diuretic use, certain drugs (insulin, beta-agonists) can drive potassium into cells.

• Hyperkalemia etiologies and mechanisms

  • Impaired renal excretion (AKI, CKD, hypoaldosteronism, ACE inhibitors/ARBs, NSAIDs), cell-shift (acidosis, insulin deficiency), increased intake, or redistribution due to catecholamines.

• Clinical implications and management

  • Hyperkalemia can cause cardiac conduction abnormalities; treat with strategies to shift K+ intracellularly (insulin with glucose, beta-agonists), stabilize membrane (calcium), and remove excess K+ (diuretics, dialytics, cation-exchange resins).

  • Hypokalemia management includes K+ supplementation and addressing underlying causes (GI losses, diuretic use, Mg repletion when needed).

• Special syndromes and genetic causes

  • Liddle syndrome (ENaC gain-of-function) → low renin/low aldosterone; treat with amiloride or triamterene; diuretic resistance patterns.

  • Gordon/GRHA (glucocorticoid-remediable hyperaldosteronism) patterns and related disorders; management with glucocorticoids and anti-mineralocorticoid strategies.

  • Bartter vs Gitelman differences summarized in the deck; Bartter mimics loop diuretic effects; Gitelman mimics thiazide effects with hypocalciuria and hypomagnesemia.

Nephrolithiasis and metabolic bone disease: stones and their pathways

• Stone types and etiologies

  • Calcium oxalate (CaOx) and calcium phosphate (CaP): most common; Ces-specific risk factors include elevated urinary calcium, low citrate, high oxalate, high uric acid, low urine volume.

  • Uric acid stones: risk with acidic urine and hyperuricosuria; management includes urine alkalinization (potassium citrate) and uric acid-lowering strategies if needed.

  • Struvite stones: associated with urease-positive bacteria (Proteus, Klebsiella); treatment typically surgical and sometimes with urease inhibitors.

  • Cystine stones: due to cystinuria (SLC3A1/SLC7A9) with low urine solubility; management includes hydration, urine alkalinization, low cystine load, and chelation (tiopronin) if refractory.

• Cystinuria and dent disease

  • Cystinuria: autosomal recessive; transporter defect (rBAT, b0,+ AT) causing poor cystine solubility and stone formation; management includes hydration, urine alkalinization, protein/cystine restriction, and chelation (tiopronin) if needed.

  • Dent disease: proximal tubulopathy with nephrocalcinosis and hypercalciuria; associated with mutations in CLCN5 and OCRL1; Mg handling and stone risk factors are highlighted in the deck.

• Prevention strategies in stones

  • Calcium stones: dietary calcium is not generally restricted; thiazide diuretics can reduce urinary calcium in hypercalciuria; potassium citrate is used for hypocitraturia; low-sodium diet is beneficial.

  • Citrate therapy: potassium citrate can raise urinary citrate and pH to discourage CaOx formation; caution with calcium phosphate stones due to pH changes.

  • Uric acid stones: urinary alkalinization (potassium citrate or sodium citrate) to raise pH above ~6.5 to solubilize uric acid.

  • Oxalate management: reduce dietary oxalate, treat malabsorption (enteric hyperoxaluria) with calcium citrate to bind intestinal oxalate; consider Oxalobacter formigenes colonization as an investigational approach.

• Practical exam ideas

  • A high urine calcium with normal PTH suggests idiopathic hypercalciuria; a high PTH with hypercalcemia suggests primary hyperparathyroidism; measurement of 24h urinary calcium and PTH is used to classify cases.

  • Stones in Crohn disease with ileal resection raise enteric hyperoxaluria; management includes low-fat diet, calcium citrate with meals to bind oxalate, hydration, and oxalate-reducing strategies.

Metabolic bone disease and vitamin D axis (brief integration)

• Calcium–PTH–Vitamin D–FGF23 axis overview

  • The parathyroid gland, bone, kidney, gut, and hormonal mediators (PTH, 25-OH vitamin D, 1,25-(OH)2D, FGF23, Klotho) regulate calcium and phosphate homeostasis.

  • Hyperparathyroidism, hypoparathyroidism, and vitamin D disorders influence calcium balance, bone turnover, and stone risk (e.g., hypercalciuria) in various contexts (nephrolithiasis, osteoporosis).

• Clinical implications

  • In calcium stone formers with high urinary calcium, measure PTH and calcium homeostasis; consider CYP24A1 mutations if PTH is not appropriately regulated.

  • Calcium supplementation, vitamin D status, and dietary calcium influence stone risk and bone health—these must be balanced in stones.

Practical equations and quick-reference toolbox for the exams

• Sodium disorders and osmolarity

  • AG: $AG=[Na^+]-([Cl^-]+[HCO_3^-])$; normal around 12; high AG implies unmeasured anions (lactate, ketoacids, toxins).

  • Osmolality gap for toxins: $ext{Osmolal gap}= ext{Posm}<em>{measured}- ext{Posm}</em>{calc}$ with $ext{Posm}_{calc}=2[Na^+]+ rac{BUN}{2.8}+ rac{Glucose}{18}$

  • UAG: $UAG=U<em>{Na}+U</em>{K}-U_{Cl}$; positive UAG suggests distal acidification defect; negative UAG suggests adequate NH4+ excretion.

  • Delta Gap: $ext{Delta Gap}=AG-12$; compare with change in bicarbonate to assess mixed disturbances.

  • Winter’s formula for pCO2 in metabolic acidosis: $pCO<em>2^{pred}=1.5[HCO</em>3^-]+8\pm 2$

  • ADH axis in AVP-driven hyponatremia is critical; use of vaptans requires caution in hypovolemic states.

• Calcium and magnesium physics (integrative points)

  • Mg handling in TAL/DCT depends on CLDN16/19 and TRPM6/TRPM7; EGFR inhibitors (cetuximab) reduce Mg reabsorption via TRPM6 downregulation.

  • Hypomagnesemia predisposes to hypocalcemia due to impaired PTH release and activity; Mg repletion often improves calcium status.

• Free water concepts in diuretic-related disorders

  • CH2O and UAG/UOG interplay under various diuretic regimens; case-based dosing adjustments require close monitoring of serum Na+.

Quick reference: key management strategies by disorder

• Hyponatremia

  • Acute symptomatic: hypertonic saline 3% NaCl, 100 mL IV over 10 min, up to 2-3 doses;

  • Chronic or asymptomatic: fluid restriction (~0.8 L/day), consider vaptans or urea if needed, DDAVP to prevent overcorrection if rapid diuresis occurs.

• Hypertonic glycerol (HTS) and hypernatremia: follows water deficit correction with careful Na+ targets; monitor for osmotic shifts.

• SIADH: fluid restriction; vaptans with caution; urea as a second-line option; consider addressing the underlying cause (tumor, infection, meds).

• DKA and osmolar disturbances: manage with insulin and fluids; monitor for normal gap acidosis during recovery; compute AG and delta gap for mixed pattern detection.

• Hypomagnesemia/hypokalemia syndromes: Mg repletion; treat underlying diuretic use; consider TRPM6/EGFR-related etiologies in drug-induced Mg loss; monitor K+ closely during Mg therapy.

• Calcium stones: calcium with meals if CaOx stones; thiazides for hypercalciuria; citrate for hypocitraturia; avoid excessive calcium restriction; consider genetic tests (CYP24A1) if abnormally high or low Ca/PTH patterns.

• Oxalate stones: hydrate; low-oxalate diet; calcium citrate with meals; consider colonization with Oxalobacter formigenes as a future strategy; assess fat malabsorption in Crohn disease.

• Magnesium disorders in critical care: magnesium homeostasis is essential in many critical state conditions; avoid overt magnesium depletion in sepsis and kidney injury.

Final take-home messages

• The kidney and hormones coordinate acid-base and electrolyte balance through a complex network of channels, transporters, and signaling pathways (e.g., ENaC, ROMK, NCC/NKCC2, CLDNs, TRPM channels, EGFR signaling).

• For board exams, the key is to recognize patterns (AG vs NAGMA, mixed disorders, DI vs SIADH, proximal vs distal RTA) and apply the correct correction strategy with attention to rates (to avoid osmotic demyelination syndrome).

• Practice with a structured approach (AG, delta, Winter’s formula, UAG/UOG, osmolal gap) and a patient-centered treatment plan that emphasizes safety and rate control.

• References and resources used in this deck include Dunlosky et al. (2013); Karpicke & Roediger; NEJM Knowledge+ board materials; and primary nephrology texts cited throughout the slides.